부산대학교 도서관

Establishing treatment goals for people living with X-linked hypophosphataemia (XLH) Background The disease burden evolves throughout the lifespan of people living with XLH, and different clinical manifestations occur at different ages in varying ranges of severity [[2], [7]]. To establish clear recommendations for the optimal treatment of people with XLH from adolescence to adulthood, existing guidance needs to be regularly reviewed and updated with real-world experience and recently published long-term trial data for burosumab, taking into account patient-centred outcomes. The XLH Matters series is a forum for international XLH expert clinicians to: share latest clinical research, including real-world data; discuss challenges with managing XLH; and identify approaches to improve the outcomes of people living with XLH. [Extracted from the article]